Table 1. Summary of the RAS analysis in this study with corresponding ELISpot responses.

Participant	HCV Genotype	Substitution detected	RAS outcomea	Positionb	Reversion	CD8 T cell epitope analysis
						Epitope sequence	HLA	Result (SFU/106 PBMC)c	Time-point (DPI)d
Ch_086MX	1a	A421V	Gain	2841	No	2841ARMVMMTHF2849	HLA-B27:05	25	72
Ch_485FX	1b	V499A	Gain	2918	No	2913GVPPLRVWR2921	HLA-A01:01	Negative	79
		S556G	Loss	2975	Yes	—	—	—	—
Cl_277	3a	M414T	Gain	2844	No	2838WLGNIIMYA2846	HLA-A02:01	45	116
Ch_240	3a	P496S	Loss	2926	Yes	—	—	—	—
Cl_686FX	1a	A553V	Gain/Loss	2973	Yes	2967LSGWFTAGY2975	HLA-A01:01	Negative	117
		S556G	Gain/Loss	2976	Yes	—	—	—	—

^aRAS; resistance-associated substitution. Gain or loss or RAS is determined longitudinally with reference to the earliest sample.

^bAmino acid position with reference to strain H77 (AF009606) for GT1a, Con1 (AJ238799) for GT1b, and NZL1 (D17763) for GT3a.

^cSpot-forming units per million peripheral blood mononuclear cells.

^dEstimated days post infection (DPI) at which analysis was performed.